

Evonik's SPHINOX® Immulance wins Ringier Technology Innovation Awards for Personal Care 2023

21 July, 2023

- A new ceramide that protects the skin by balancing the skin's immune barrier
- Reinforces Evonik's leading position as a preferred sustainable specialties partner for the personal care industry
- Ringier Technology Innovation Awards for Personal Care are among the most prestigious awards in China's beauty industry

Main press contact

Jana Flommersfeld
Head of Market Communications
Care Solutions
Phone + 49 201 173-3772
jana.flommersfeld@evonik.com

Regional press contact

Elaine Yang
Corporate Communications
Phone +86 21 6119 1293
elaine.yang@evonik.com

Shanghai/China. Evonik has received the Ringier Technology Innovation Awards for Personal Care 2023 for its newly launched ceramide SPHINOX® Immulance, which protects the skin by balancing its immune barrier. This is the fifth consecutive year that the Care Solutions business at Evonik has been recognized by the local industry for its innovations that deliver superior outcomes in sustainability and functionality.

Evonik's Care Solutions business is guided by a vision that puts sustainability, innovation and collaboration at its core. Ceramides are an integral part of many System Solutions for customers in the cosmetics industry. System Solutions are multi-component offerings across products, technologies and services that are tailored to a unique customer need and often have proven sustainability benefits. The life sciences division at Evonik, Nutrition & Care is home to the Care Solutions business and has a goal of increasing its share of System Solutions from 20 percent today to 50 percent by 2030.

"This award recognizes Evonik's consistent efforts to decode the full potential of ceramides, which are becoming increasingly popular with end-consumers in China," says Madeline Tan, regional business director in Asia North of Evonik's Care Solutions business line, "we will continue to support local customers with innovative and scientifically proven solutions that enable and enhance their formulations to meet the more diversified market demands."

Evonik Industries AG

Rellinghauser Straße 1-11
45128 Essen
Germany
Phone +49 201 177-01
www.evonik.com

Supervisory Board
Bernd Tönjes, Chairman
Executive Board
Christian Kullmann, Chairman
Dr. Harald Schwager, Deputy Chairman
Maike Schuh, Thomas Wessel

Registered Office is Essen
Register Court Essen Local Court
Commercial Registry B 19474

SPHINOX® Immulance is a unique ceramide based on uneven fatty acid side chains that are known for its various health benefits as a food supplement. With this new product, Evonik is the first to explore ceramides with odd-numbered fatty acids and their cosmetic benefits. In combination with phytosphingosine as a base, SPHINOX® Immulance boosts the skin's antimicrobial defense mechanisms by induction of antimicrobial peptides, strengthens the skin's immune barrier and soothes overreactive skin.

Company information

Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €18.5 billion and an operating profit (adjusted EBITDA) of €2.49 billion in 2022. Evonik goes far beyond chemistry to create innovative, profitable, and sustainable solutions for customers. About 34,000 employees work together for a common purpose: We want to improve life today and tomorrow.

About Nutrition & Care

The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of €4.24 billion in 2022 with about 5,700 employees.

Disclaimer

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.